|Dr. Ahmed M. Hamdy||Founder, Chairman & CEO||622.05k||N/A||1965|
|Dr. Raquel E. Izumi||Founder, Pres, COO, Sec. & Director||652.84k||N/A||1970|
|Mr. Alexander A. Seelenberger M.B.A., MBA||Chief Financial Officer||405.46k||N/A||1979|
|Mr. Stuart Hwang Ph.D.||Chief Bus. Officer & Founder||N/A||N/A||N/A|
|Mr. Tom C. Thomas||Founder, Gen. Counsel & Chief Legal Officer||N/A||N/A||1960|
|Dr. John C. Byrd M.D.||Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Xiaoming Zhang Ph.D.||Chief Technical Officer||N/A||N/A||1964|
|Dr. Hans-Georg Lerchen Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Hermes Garban M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1968|
|Dr. David Nganele M.B.A., Ph.D.||Head of Early Devel.||N/A||N/A||N/A|
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
Vincerx Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.